These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy. Ferri C; Bianchini M; Bengió R; Larripa I Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144 [TBL] [Abstract][Full Text] [Related]
4. New Developments in Chronic Myeloid Leukemia: Implications for Therapy. Tabarestani S; Movafagh A Iran J Cancer Prev; 2016 Feb; 9(1):e3961. PubMed ID: 27366312 [TBL] [Abstract][Full Text] [Related]
5. Characterization of cancer stem cells in chronic myeloid leukaemia. Jørgensen HG; Holyoake TL Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348 [TBL] [Abstract][Full Text] [Related]
6. Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-κB pathways in a model of chronic myeloid leukemia. Chorzalska A; Ahsan N; Rao RSP; Roder K; Yu X; Morgan J; Tepper A; Hines S; Zhang P; Treaba DO; Zhao TC; Olszewski AJ; Reagan JL; Liang O; Gruppuso PA; Dubielecka PM Mol Oncol; 2018 May; 12(5):630-647. PubMed ID: 29485707 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of isoprenylcysteine carboxylmethyltransferase augments BCR-ABL1 tyrosine kinase inhibition-induced apoptosis in chronic myeloid leukemia. Sun WT; Xiang W; Ng BL; Asari K; Bunte RM; Casey PJ; Wang M; Chuah C Exp Hematol; 2016 Mar; 44(3):189-93.e2. PubMed ID: 26706195 [TBL] [Abstract][Full Text] [Related]
8. Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors. Mancini M; De Santis S; Monaldi C; Bavaro L; Martelli M; Castagnetti F; Gugliotta G; Rosti G; Santucci MA; Martinelli G; Cavo M; Soverini S J Exp Clin Cancer Res; 2019 May; 38(1):216. PubMed ID: 31122263 [TBL] [Abstract][Full Text] [Related]
9. Repurposing the Bis-Biguanide Alexidine in Combination with Tyrosine Kinase Inhibitors to Eliminate Leukemic Stem/Progenitor Cells in Chronic Myeloid Leukemia. Muselli F; Mourgues L; Rochet N; Nebout M; Guerci A; Verhoeyen E; Krug A; Legros L; Peyron JF; Mary D Cancers (Basel); 2023 Feb; 15(3):. PubMed ID: 36765952 [TBL] [Abstract][Full Text] [Related]
10. A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Wagle M; Eiring AM; Wongchenko M; Lu S; Guan Y; Wang Y; Lackner M; Amler L; Hampton G; Deininger MW; O'Hare T; Yan Y Leukemia; 2016 Jul; 30(7):1493-501. PubMed ID: 27044711 [TBL] [Abstract][Full Text] [Related]
12. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation. Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872 [TBL] [Abstract][Full Text] [Related]
13. Molecular techniques for the personalised management of patients with chronic myeloid leukaemia. Alikian M; Gale RP; Apperley JF; Foroni L Biomol Detect Quantif; 2017 Mar; 11():4-20. PubMed ID: 28331814 [TBL] [Abstract][Full Text] [Related]
14. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy. Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of Tumoral VISTA to Overcome TKI Resistance via Downregulation of the AKT/mTOR and JAK2/STAT5 Pathways in Chronic Myeloid Leukemia. Ai K; Chen M; Liang Z; Ding X; Gao Y; Zhang H; Wu S; He Y; Li Y Biomol Ther (Seoul); 2024 Sep; 32(5):582-600. PubMed ID: 39104205 [TBL] [Abstract][Full Text] [Related]
17. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Topaly J; Zeller WJ; Fruehauf S Leukemia; 2001 Mar; 15(3):342-7. PubMed ID: 11237055 [TBL] [Abstract][Full Text] [Related]
18. BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia. Roy S; Jørgensen HG; Roy P; Abed El Baky M; Melo JV; Strathdee G; Holyoake TL; Bartholomew C Br J Haematol; 2012 May; 157(4):446-56. PubMed ID: 22372463 [TBL] [Abstract][Full Text] [Related]
19. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function. Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074 [TBL] [Abstract][Full Text] [Related]
20. Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia. Tiribelli M; Eskazan AE Oncol Ther; 2019 Dec; 7(2):95-100. PubMed ID: 32699984 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]